Search clinical trials for: Glargine

Total 578 results

Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico
Sanofi

Completed

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine (SORELLA2)

Type 2 Diabetes Mellitus

United States, Argentina, Chile, Colombia, Germany, Hungary, Italy, Korea, Republic of, Romania, Russian Federation, Spain, Turkey
Sanofi

Completed

Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus (PORTAL 1)

Diabetes Mellitus, Type 1

Belarus
Sanofi

Completed

Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin

Diabetes Mellitus, Type 2

United States
Handok Inc.

Completed

Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Korea, Republic of
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

India, Israel, Russian Federation, United Kingdom, Taiwan, Argentina, Finland, Hungary, Macedonia, The Former Yugoslav Republic of, Malaysia, Mexico, Norway, Serbia, South Africa
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Sanofi

Completed

Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2

Turkey
Sanofi

Completed

Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

France, Russian Federation, Croatia, Slovenia, Czech Republic, Romania
Inova Health Care Services

Terminated

Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, United Kingdom, France, Netherlands, Finland, Germany, Sweden
AstraZeneca
Eli Lilly and Company

Completed

Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Finland, Netherlands, Sweden
AstraZeneca
Eli Lilly and Company

Completed

Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

Type 2 Diabetes Mellitus

Italy, Poland, Hungary, Mexico, Greece, Australia
Novo Nordisk A/S

Completed

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, India, South Africa, Canada
Sanofi

Completed

Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day (SeLan)

Diabetes Mellitus, Type 2

Israel
AstraZeneca
Eli Lilly and Company

Completed

A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients

Type 2 Diabetes

United Kingdom
Emory University
Sanofi

Completed

Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery (RABBIT 2-SX)

Type 2 Diabetes | Inpatient Hyperglycemia

United States
University of Maryland, Baltimore

Completed

Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

Diabetic Ketoacidosis

United States
Tehran University of Medical Sciences

Completed

Cost Effectiveness of Glargine Insulin Versus NPH Insulin

Type 2 Diabetes Mellitus

Iran, Islamic Republic of
Profil Institut für Stoffwechselforschung GmbH
Sanofi

Completed

Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes

Type 2 Diabetes

Germany
Eli Lilly and Company

Completed

A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Eli Lilly and Company

Completed

A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics

Type 1 Diabetes Mellitus

United States
Sanofi

Completed

PUMP STUDY MDI Lantus/Lispro vs Continuous Insulin+Lispro

Diabetes Mellitus
Sanofi

Completed

Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine (QoL)

Diabetes Type 2

Sweden
University Hospital Tuebingen

Active, not recruiting

Empagliflozin Effect on Glucose Toxicity

Type2 Diabetes Mellitus

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Puerto Rico
AstraZeneca
Eli Lilly and Company

Completed

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

Diabetes Mellitus, Type 2

Belgium, United States, Australia, Portugal, Germany, Puerto Rico, Spain, Netherlands, Brazil, Finland, Norway, Poland, Sweden
Sanofi

Completed

baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus (SUBSTITUTE)

Diabetes Mellitus, Type 1

Tunisia, South Africa, Algeria, Argentina, Brazil, Colombia, Kuwait, Mexico, Saudi Arabia
Charles Drew University of Medicine and Science
National Center for Research Resources (NCRR)

Completed

Insulin Glargine at Bedtime or in AM Versus NPH

Type 2 Diabetes Mellitus

United States
Fudan University
Shanghai Changzheng Hospital; Shanghai 6th People's Hospital; Shanghai Minhang... and other collaborators

Completed

Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Non-alcoholic Fatty Liver Disease

China
Novo Nordisk A/S

Completed

Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany, Austria, South Africa
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Sweden, Finland, France, Norway
Sanofi

Terminated

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment (TRENT)

Type 2 Diabetes Mellitus | Renal Impairment

United States, Czechia, Hungary, Poland, Serbia
US Department of Veterans Affairs

Completed

Insulin Secretion in Diabetes Before and After Glycemic Control

Hyperglycemia | Diabetes

United States
Sanofi

Completed

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure (EAGLE)

Diabetes Mellitus, Type 2

Brazil, United States, Finland, Spain, Austria, Canada, Czech Republic, France, Greece, Ireland, Israel, Mexico, Netherlands, Russian Federation, Slovakia, Sweden, Turkey
Eli Lilly and Company

Completed

Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX) (IOOX)

Diabetes Mellitus, Type 2

Australia, Russian Federation, Spain, Mexico, Canada, France, Korea, Republic of
Sanofi

Completed

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) (Lixilan-O-AP)

Type 2 Diabetes Mellitus

China, Korea, Republic of, Malaysia, Taiwan
Daiichi Sankyo, Inc.

Completed

Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Sanofi

Completed

Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial) (AT-LANTUS)

Diabetes Mellitus, Type 1
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan (LIXILAN JP-O1)

Type 2 Diabetes Mellitus

Japan
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Completed

A Comparison of Exenatide and Insulin Glargine

Type 2 Diabetes

China
Sanofi

Completed

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs (CHANGING)

Diabetes Mellitus, Type 2

Algeria, Brazil, Israel, Lebanon, Mexico, Morocco, Peru, Saudi Arabia, United Arab Emirates, Venezuela
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin (Reach-Control)

Diabetes Mellitus, Type 2

Germany, Spain, Brazil, France, Ireland, Romania, United Kingdom
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (REGAIN CONTROL)

Diabetes Mellitus, Type 2

Italy, Ireland, Spain, Greece, Finland, Romania, Brazil, United Kingdom, France, Switzerland
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs

Type 2 Diabetes

China
Eli Lilly and Company

Completed

A Study of LY2963016 in Healthy Participants

Healthy Volunteers

Singapore
Eli Lilly and Company

Completed

A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects

Diabetes Mellitus

Singapore
Sanofi

Completed

Glycemic Optimization Treatment Study (GOT)

Diabetes Mellitus, Type 2
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Turkey
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus (DUALTM IX)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Canada, Spain, Switzerland, Argentina, Finland, Hungary, Russian Federation, Slovenia, Slovakia

3

Subscribe